TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases

DOI Web Site Web Site 1 Citations
  • Juliane Totzke
    Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA
  • Scott A. Scarneo
    Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA
  • Kelly W. Yang
    Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA
  • Timothy A. J. Haystead
    Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA

Description

<jats:p>Aberrant tumour necrosis factor (TNF) signalling is a hallmark of many inflammatory diseases including rheumatoid arthritis (RA), irritable bowel disease and lupus. Maladaptive TNF signalling can lead to hyper active downstream nuclear factor (NF)-κβ signalling in turn amplifying a cell's inflammatory response and exacerbating disease. Within the TNF intracellular inflammatory signalling cascade, transforming growth factor-β-activated kinase 1 (TAK1) has been shown to play a critical role in mediating signal transduction and downstream NF-κβ activation. Owing to its role in TNF inflammatory signalling, TAK1 has become a potential therapeutic target for the treatment of inflammatory diseases such as RA. This review highlights the current development of targeting the TNF-TAK1 signalling axis as a novel therapeutic strategy for the treatment of inflammatory diseases.</jats:p>

Journal

  • Open Biology

    Open Biology 10 (9), 1-, 2020-09

    The Royal Society

Citations (1)*help

See more

Report a problem

Back to top